Compare HUDI & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUDI | XCUR |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 13.7M |
| IPO Year | 2019 | 2017 |
| Metric | HUDI | XCUR |
|---|---|---|
| Price | $0.95 | $1.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 836.2K | 40.9K |
| Earning Date | 01-30-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.66 | $1.05 |
| 52 Week High | $5.46 | $9.48 |
| Indicator | HUDI | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 56.30 | 30.78 |
| Support Level | $0.90 | N/A |
| Resistance Level | $1.33 | $2.02 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 58.95 | 20.00 |
Huadi International Group Co Ltd is a manufacturer of industrial stainless steel seamless pipes and tubes products. Its products are used in the oil & gas transmission, chemistry engineering, food processing, medical devices, aeronautics and astronautics, boiler, irrigation works construction, automobile and naval architecture, paper mill and mechanical industries. Company generates revenue from Sales of steel piping products. Products are exported to the United States, Mexico, Thailand, Singapore, Argentina, Taiwan, India, the Philippines, UAE and Canada. Geographically, majority revenue is generated from China.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.